OPKO HEALTH, INC.
OPK · XNASCIK 944809fmd_0MVH4JR74ZAJZZTEQHKKNE3YJNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1,117 | 966 | 990 | 902 | 1,435 | 1,775 | 1,004 | 863 | 713 | 607 |
| Cost of revenue | 47 | 61 | – | – | – | – | 716 | 545 | 495 | 401 |
| Gross profit | 1,070 | 905 | – | – | – | – | 288 | 318 | 219 | 206 |
| Realized investment gains (losses) | (8) | (14) | (14) | (3) | (0) | (1) | (0) | (0) | – | – |
| Research and development | 114 | 126 | 126 | 118 | 75 | 77 | 74 | 90 | 105 | 124 |
| Selling, general and administrative | 407 | 415 | 358 | 343 | 356 | 469 | 373 | 301 | 304 | 223 |
| Total operating expenses | 1,214 | 1,242 | 1,161 | 1,176 | 1,378 | 1,756 | 1,230 | 1,021 | – | – |
| Operating income | (97) | (276) | (171) | (274) | 58 | 19 | (226) | (157) | (152) | (117) |
| Interest expense | – | – | – | – | – | 19 | 12 | 14 | 47 | 0 |
| Interest and investment income | – | – | – | – | – | 0 | 2 | 4 | 8 | 15 |
| Other non-operating income (expense) | (0) | 5 | (6) | (31) | (9) | (33) | (165) | (27) | 142 | (124) |
| Income before taxes | (97) | (272) | (177) | (305) | 49 | (14) | (392) | (184) | (10) | (241) |
| Income tax expense | (56) | 19 | (39) | 7 | 18 | 15 | (63) | 4 | 43 | (16) |
| Net income from continuing operations | (41) | (291) | (139) | (312) | 31 | (30) | (328) | (189) | (53) | (226) |
| Net income | (48) | (305) | (153) | (315) | 31 | (30) | (328) | (189) | (53) | (226) |
| Net income to common shareholders | (48) | (305) | (153) | – | – | – | – | – | – | – |